nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—Bromocriptine—type 2 diabetes mellitus	0.396	1	CrCtD
Dihydroergotamine—Ergoloid mesylate—Bromocriptine—type 2 diabetes mellitus	0.153	0.663	CrCrCtD
Dihydroergotamine—ADRA2A—type 2 diabetes mellitus	0.086	0.685	CbGaD
Dihydroergotamine—Ergotamine—Bromocriptine—type 2 diabetes mellitus	0.0774	0.337	CrCrCtD
Dihydroergotamine—CYP3A4—type 2 diabetes mellitus	0.0395	0.315	CbGaD
Dihydroergotamine—HTR6—Bromocriptine—type 2 diabetes mellitus	0.0213	0.127	CbGbCtD
Dihydroergotamine—HTR1D—Bromocriptine—type 2 diabetes mellitus	0.0194	0.115	CbGbCtD
Dihydroergotamine—HTR2B—Bromocriptine—type 2 diabetes mellitus	0.019	0.113	CbGbCtD
Dihydroergotamine—HTR1B—Bromocriptine—type 2 diabetes mellitus	0.0186	0.111	CbGbCtD
Dihydroergotamine—HTR1A—Bromocriptine—type 2 diabetes mellitus	0.0117	0.0693	CbGbCtD
Dihydroergotamine—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0111	0.0663	CbGbCtD
Dihydroergotamine—ABCB1—Linagliptin—type 2 diabetes mellitus	0.00888	0.0529	CbGbCtD
Dihydroergotamine—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.00792	0.0471	CbGbCtD
Dihydroergotamine—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00573	0.0341	CbGbCtD
Dihydroergotamine—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00532	0.0317	CbGbCtD
Dihydroergotamine—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00474	0.0282	CbGbCtD
Dihydroergotamine—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00434	0.0258	CbGbCtD
Dihydroergotamine—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00393	0.0234	CbGbCtD
Dihydroergotamine—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00379	0.0226	CbGbCtD
Dihydroergotamine—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00343	0.0204	CbGbCtD
Dihydroergotamine—ABCB1—Glyburide—type 2 diabetes mellitus	0.00293	0.0174	CbGbCtD
Dihydroergotamine—ABCB1—Losartan—type 2 diabetes mellitus	0.00268	0.016	CbGbCtD
Dihydroergotamine—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0026	0.0155	CbGbCtD
Dihydroergotamine—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00249	0.0148	CbGbCtD
Dihydroergotamine—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00249	0.0148	CbGbCtD
Dihydroergotamine—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00236	0.014	CbGbCtD
Dihydroergotamine—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00176	0.0105	CbGbCtD
Dihydroergotamine—CYP3A4—Losartan—type 2 diabetes mellitus	0.00161	0.00956	CbGbCtD
Dihydroergotamine—Ergoloid mesylate—CYP3A4—type 2 diabetes mellitus	0.000183	0.163	CrCbGaD
Dihydroergotamine—Ergotamine—ADRA2A—type 2 diabetes mellitus	0.000155	0.139	CrCbGaD
Dihydroergotamine—Bromocriptine—ADRA2A—type 2 diabetes mellitus	0.00015	0.134	CrCbGaD
Dihydroergotamine—Ergotamine—HTR2C—type 2 diabetes mellitus	0.000143	0.128	CrCbGaD
Dihydroergotamine—Bromocriptine—HTR2C—type 2 diabetes mellitus	0.000138	0.123	CrCbGaD
Dihydroergotamine—Ergotamine—CYP1A2—type 2 diabetes mellitus	0.000108	0.0962	CrCbGaD
Dihydroergotamine—Bromocriptine—CYP1A2—type 2 diabetes mellitus	0.000104	0.0928	CrCbGaD
Dihydroergotamine—HTR1B—artery—type 2 diabetes mellitus	8.52e-05	0.144	CbGeAlD
Dihydroergotamine—HTR1D—artery—type 2 diabetes mellitus	8.25e-05	0.14	CbGeAlD
Dihydroergotamine—Ergotamine—CYP3A4—type 2 diabetes mellitus	7.14e-05	0.0637	CrCbGaD
Dihydroergotamine—Bromocriptine—CYP3A4—type 2 diabetes mellitus	6.88e-05	0.0614	CrCbGaD
Dihydroergotamine—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	6.13e-05	0.104	CbGeAlD
Dihydroergotamine—Urticaria—Glyburide—type 2 diabetes mellitus	4.34e-05	0.000802	CcSEcCtD
Dihydroergotamine—Nervousness—Losartan—type 2 diabetes mellitus	4.34e-05	0.000801	CcSEcCtD
Dihydroergotamine—Abdominal pain—Glyburide—type 2 diabetes mellitus	4.32e-05	0.000798	CcSEcCtD
Dihydroergotamine—Dyspepsia—Gliclazide—type 2 diabetes mellitus	4.32e-05	0.000798	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	4.3e-05	0.000795	CcSEcCtD
Dihydroergotamine—Anorexia—Valsartan—type 2 diabetes mellitus	4.29e-05	0.000794	CcSEcCtD
Dihydroergotamine—Muscle spasms—Losartan—type 2 diabetes mellitus	4.29e-05	0.000793	CcSEcCtD
Dihydroergotamine—Asthenia—Bromocriptine—type 2 diabetes mellitus	4.29e-05	0.000792	CcSEcCtD
Dihydroergotamine—Myalgia—Metformin—type 2 diabetes mellitus	4.28e-05	0.000791	CcSEcCtD
Dihydroergotamine—Malaise—Irbesartan—type 2 diabetes mellitus	4.28e-05	0.000791	CcSEcCtD
Dihydroergotamine—Vertigo—Irbesartan—type 2 diabetes mellitus	4.26e-05	0.000788	CcSEcCtD
Dihydroergotamine—Headache—Pioglitazone—type 2 diabetes mellitus	4.26e-05	0.000787	CcSEcCtD
Dihydroergotamine—Visual impairment—Ramipril—type 2 diabetes mellitus	4.24e-05	0.000783	CcSEcCtD
Dihydroergotamine—Discomfort—Metformin—type 2 diabetes mellitus	4.23e-05	0.000782	CcSEcCtD
Dihydroergotamine—Fatigue—Gliclazide—type 2 diabetes mellitus	4.23e-05	0.000781	CcSEcCtD
Dihydroergotamine—Nausea—Glipizide—type 2 diabetes mellitus	4.21e-05	0.000779	CcSEcCtD
Dihydroergotamine—Vomiting—Glimepiride—type 2 diabetes mellitus	4.21e-05	0.000778	CcSEcCtD
Dihydroergotamine—Hypotension—Valsartan—type 2 diabetes mellitus	4.21e-05	0.000778	CcSEcCtD
Dihydroergotamine—Vomiting—Sitagliptin—type 2 diabetes mellitus	4.2e-05	0.000776	CcSEcCtD
Dihydroergotamine—Pain—Gliclazide—type 2 diabetes mellitus	4.19e-05	0.000775	CcSEcCtD
Dihydroergotamine—Tremor—Losartan—type 2 diabetes mellitus	4.18e-05	0.000773	CcSEcCtD
Dihydroergotamine—Rash—Glimepiride—type 2 diabetes mellitus	4.17e-05	0.000772	CcSEcCtD
Dihydroergotamine—Dermatitis—Glimepiride—type 2 diabetes mellitus	4.17e-05	0.000771	CcSEcCtD
Dihydroergotamine—Rash—Sitagliptin—type 2 diabetes mellitus	4.16e-05	0.000769	CcSEcCtD
Dihydroergotamine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	4.16e-05	0.000769	CcSEcCtD
Dihydroergotamine—Headache—Glimepiride—type 2 diabetes mellitus	4.15e-05	0.000767	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Losartan—type 2 diabetes mellitus	4.14e-05	0.000766	CcSEcCtD
Dihydroergotamine—Headache—Sitagliptin—type 2 diabetes mellitus	4.13e-05	0.000764	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	4.1e-05	0.000759	CcSEcCtD
Dihydroergotamine—Agitation—Losartan—type 2 diabetes mellitus	4.1e-05	0.000758	CcSEcCtD
Dihydroergotamine—Oedema—Metformin—type 2 diabetes mellitus	4.1e-05	0.000758	CcSEcCtD
Dihydroergotamine—Tinnitus—Ramipril—type 2 diabetes mellitus	4.1e-05	0.000758	CcSEcCtD
Dihydroergotamine—Hypertension—Irbesartan—type 2 diabetes mellitus	4.09e-05	0.000757	CcSEcCtD
Dihydroergotamine—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	4.09e-05	0.000755	CcSEcCtD
Dihydroergotamine—Flushing—Ramipril—type 2 diabetes mellitus	4.08e-05	0.000754	CcSEcCtD
Dihydroergotamine—Insomnia—Valsartan—type 2 diabetes mellitus	4.07e-05	0.000753	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	4.06e-05	0.00075	CcSEcCtD
Dihydroergotamine—Paraesthesia—Valsartan—type 2 diabetes mellitus	4.04e-05	0.000748	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	4.04e-05	0.000747	CcSEcCtD
Dihydroergotamine—Arthralgia—Irbesartan—type 2 diabetes mellitus	4.04e-05	0.000746	CcSEcCtD
Dihydroergotamine—Myalgia—Irbesartan—type 2 diabetes mellitus	4.04e-05	0.000746	CcSEcCtD
Dihydroergotamine—Shock—Metformin—type 2 diabetes mellitus	4.04e-05	0.000746	CcSEcCtD
Dihydroergotamine—Insomnia—Orlistat—type 2 diabetes mellitus	4.03e-05	0.000744	CcSEcCtD
Dihydroergotamine—Malaise—Losartan—type 2 diabetes mellitus	4.03e-05	0.000744	CcSEcCtD
Dihydroergotamine—Anxiety—Irbesartan—type 2 diabetes mellitus	4.02e-05	0.000744	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	4.02e-05	0.000744	CcSEcCtD
Dihydroergotamine—Dyspnoea—Valsartan—type 2 diabetes mellitus	4.02e-05	0.000742	CcSEcCtD
Dihydroergotamine—Vertigo—Losartan—type 2 diabetes mellitus	4.01e-05	0.000741	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	4.01e-05	0.000741	CcSEcCtD
Dihydroergotamine—Somnolence—Valsartan—type 2 diabetes mellitus	4e-05	0.00074	CcSEcCtD
Dihydroergotamine—Paraesthesia—Orlistat—type 2 diabetes mellitus	4e-05	0.000739	CcSEcCtD
Dihydroergotamine—Discomfort—Irbesartan—type 2 diabetes mellitus	3.99e-05	0.000738	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	3.97e-05	0.000733	CcSEcCtD
Dihydroergotamine—Dyspepsia—Valsartan—type 2 diabetes mellitus	3.96e-05	0.000733	CcSEcCtD
Dihydroergotamine—Dizziness—Bromocriptine—type 2 diabetes mellitus	3.95e-05	0.00073	CcSEcCtD
Dihydroergotamine—Dry mouth—Irbesartan—type 2 diabetes mellitus	3.95e-05	0.00073	CcSEcCtD
Dihydroergotamine—Palpitations—Losartan—type 2 diabetes mellitus	3.94e-05	0.000729	CcSEcCtD
Dihydroergotamine—Nausea—Glimepiride—type 2 diabetes mellitus	3.93e-05	0.000727	CcSEcCtD
Dihydroergotamine—Nausea—Sitagliptin—type 2 diabetes mellitus	3.92e-05	0.000725	CcSEcCtD
Dihydroergotamine—Dyspepsia—Orlistat—type 2 diabetes mellitus	3.92e-05	0.000724	CcSEcCtD
Dihydroergotamine—Asthenia—Glyburide—type 2 diabetes mellitus	3.92e-05	0.000724	CcSEcCtD
Dihydroergotamine—Decreased appetite—Valsartan—type 2 diabetes mellitus	3.92e-05	0.000724	CcSEcCtD
Dihydroergotamine—Anorexia—Metformin—type 2 diabetes mellitus	3.91e-05	0.000723	CcSEcCtD
Dihydroergotamine—Urticaria—Gliclazide—type 2 diabetes mellitus	3.89e-05	0.00072	CcSEcCtD
Dihydroergotamine—Fatigue—Valsartan—type 2 diabetes mellitus	3.88e-05	0.000718	CcSEcCtD
Dihydroergotamine—Body temperature increased—Gliclazide—type 2 diabetes mellitus	3.88e-05	0.000716	CcSEcCtD
Dihydroergotamine—Abdominal pain—Gliclazide—type 2 diabetes mellitus	3.88e-05	0.000716	CcSEcCtD
Dihydroergotamine—Oedema—Irbesartan—type 2 diabetes mellitus	3.87e-05	0.000716	CcSEcCtD
Dihydroergotamine—Decreased appetite—Orlistat—type 2 diabetes mellitus	3.87e-05	0.000715	CcSEcCtD
Dihydroergotamine—Pruritus—Glyburide—type 2 diabetes mellitus	3.86e-05	0.000714	CcSEcCtD
Dihydroergotamine—Fatigue—Orlistat—type 2 diabetes mellitus	3.84e-05	0.000709	CcSEcCtD
Dihydroergotamine—Hypotension—Metformin—type 2 diabetes mellitus	3.83e-05	0.000709	CcSEcCtD
Dihydroergotamine—Shock—Irbesartan—type 2 diabetes mellitus	3.81e-05	0.000704	CcSEcCtD
Dihydroergotamine—Pain—Orlistat—type 2 diabetes mellitus	3.81e-05	0.000704	CcSEcCtD
Dihydroergotamine—Myalgia—Losartan—type 2 diabetes mellitus	3.8e-05	0.000703	CcSEcCtD
Dihydroergotamine—Arthralgia—Losartan—type 2 diabetes mellitus	3.8e-05	0.000703	CcSEcCtD
Dihydroergotamine—Vomiting—Bromocriptine—type 2 diabetes mellitus	3.8e-05	0.000702	CcSEcCtD
Dihydroergotamine—Anxiety—Losartan—type 2 diabetes mellitus	3.79e-05	0.0007	CcSEcCtD
Dihydroergotamine—Tachycardia—Irbesartan—type 2 diabetes mellitus	3.78e-05	0.000698	CcSEcCtD
Dihydroergotamine—Rash—Bromocriptine—type 2 diabetes mellitus	3.77e-05	0.000696	CcSEcCtD
Dihydroergotamine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	3.76e-05	0.000696	CcSEcCtD
Dihydroergotamine—Tension—Ramipril—type 2 diabetes mellitus	3.76e-05	0.000694	CcSEcCtD
Dihydroergotamine—Discomfort—Losartan—type 2 diabetes mellitus	3.75e-05	0.000694	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	3.74e-05	0.000692	CcSEcCtD
Dihydroergotamine—Headache—Bromocriptine—type 2 diabetes mellitus	3.74e-05	0.000692	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	3.74e-05	0.000691	CcSEcCtD
Dihydroergotamine—Diarrhoea—Glyburide—type 2 diabetes mellitus	3.74e-05	0.000691	CcSEcCtD
Dihydroergotamine—Nervousness—Ramipril—type 2 diabetes mellitus	3.72e-05	0.000687	CcSEcCtD
Dihydroergotamine—Dry mouth—Losartan—type 2 diabetes mellitus	3.72e-05	0.000687	CcSEcCtD
Dihydroergotamine—Anorexia—Irbesartan—type 2 diabetes mellitus	3.69e-05	0.000682	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	3.68e-05	0.000681	CcSEcCtD
Dihydroergotamine—Paraesthesia—Metformin—type 2 diabetes mellitus	3.68e-05	0.000681	CcSEcCtD
Dihydroergotamine—Muscle spasms—Ramipril—type 2 diabetes mellitus	3.68e-05	0.00068	CcSEcCtD
Dihydroergotamine—Confusional state—Losartan—type 2 diabetes mellitus	3.67e-05	0.000679	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Orlistat—type 2 diabetes mellitus	3.67e-05	0.000678	CcSEcCtD
Dihydroergotamine—Dyspnoea—Metformin—type 2 diabetes mellitus	3.66e-05	0.000676	CcSEcCtD
Dihydroergotamine—Somnolence—Metformin—type 2 diabetes mellitus	3.65e-05	0.000674	CcSEcCtD
Dihydroergotamine—Oedema—Losartan—type 2 diabetes mellitus	3.64e-05	0.000673	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	3.64e-05	0.000673	CcSEcCtD
Dihydroergotamine—Hypotension—Irbesartan—type 2 diabetes mellitus	3.62e-05	0.000669	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	3.61e-05	0.000668	CcSEcCtD
Dihydroergotamine—Dyspepsia—Metformin—type 2 diabetes mellitus	3.61e-05	0.000667	CcSEcCtD
Dihydroergotamine—Tremor—Ramipril—type 2 diabetes mellitus	3.59e-05	0.000663	CcSEcCtD
Dihydroergotamine—Shock—Losartan—type 2 diabetes mellitus	3.58e-05	0.000663	CcSEcCtD
Dihydroergotamine—Urticaria—Valsartan—type 2 diabetes mellitus	3.58e-05	0.000662	CcSEcCtD
Dihydroergotamine—Decreased appetite—Metformin—type 2 diabetes mellitus	3.57e-05	0.000659	CcSEcCtD
Dihydroergotamine—Abdominal pain—Valsartan—type 2 diabetes mellitus	3.56e-05	0.000658	CcSEcCtD
Dihydroergotamine—Tachycardia—Losartan—type 2 diabetes mellitus	3.56e-05	0.000657	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	3.55e-05	0.000656	CcSEcCtD
Dihydroergotamine—Nausea—Bromocriptine—type 2 diabetes mellitus	3.55e-05	0.000656	CcSEcCtD
Dihydroergotamine—Fatigue—Metformin—type 2 diabetes mellitus	3.54e-05	0.000654	CcSEcCtD
Dihydroergotamine—Urticaria—Orlistat—type 2 diabetes mellitus	3.54e-05	0.000654	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	3.53e-05	0.000652	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	3.52e-05	0.000651	CcSEcCtD
Dihydroergotamine—Body temperature increased—Orlistat—type 2 diabetes mellitus	3.52e-05	0.00065	CcSEcCtD
Dihydroergotamine—Abdominal pain—Orlistat—type 2 diabetes mellitus	3.52e-05	0.00065	CcSEcCtD
Dihydroergotamine—Asthenia—Gliclazide—type 2 diabetes mellitus	3.52e-05	0.00065	CcSEcCtD
Dihydroergotamine—Agitation—Ramipril—type 2 diabetes mellitus	3.52e-05	0.00065	CcSEcCtD
Dihydroergotamine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	3.48e-05	0.000643	CcSEcCtD
Dihydroergotamine—Anorexia—Losartan—type 2 diabetes mellitus	3.47e-05	0.000642	CcSEcCtD
Dihydroergotamine—Vomiting—Glyburide—type 2 diabetes mellitus	3.47e-05	0.000642	CcSEcCtD
Dihydroergotamine—Pruritus—Gliclazide—type 2 diabetes mellitus	3.47e-05	0.000641	CcSEcCtD
Dihydroergotamine—Malaise—Ramipril—type 2 diabetes mellitus	3.45e-05	0.000638	CcSEcCtD
Dihydroergotamine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	3.45e-05	0.000638	CcSEcCtD
Dihydroergotamine—Rash—Glyburide—type 2 diabetes mellitus	3.44e-05	0.000636	CcSEcCtD
Dihydroergotamine—Somnolence—Irbesartan—type 2 diabetes mellitus	3.44e-05	0.000636	CcSEcCtD
Dihydroergotamine—Dermatitis—Glyburide—type 2 diabetes mellitus	3.44e-05	0.000636	CcSEcCtD
Dihydroergotamine—Vertigo—Ramipril—type 2 diabetes mellitus	3.44e-05	0.000636	CcSEcCtD
Dihydroergotamine—Headache—Glyburide—type 2 diabetes mellitus	3.42e-05	0.000632	CcSEcCtD
Dihydroergotamine—Dyspepsia—Irbesartan—type 2 diabetes mellitus	3.41e-05	0.00063	CcSEcCtD
Dihydroergotamine—Hypotension—Losartan—type 2 diabetes mellitus	3.4e-05	0.000629	CcSEcCtD
Dihydroergotamine—Palpitations—Ramipril—type 2 diabetes mellitus	3.38e-05	0.000625	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Metformin—type 2 diabetes mellitus	3.38e-05	0.000625	CcSEcCtD
Dihydroergotamine—Decreased appetite—Irbesartan—type 2 diabetes mellitus	3.36e-05	0.000622	CcSEcCtD
Dihydroergotamine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	3.35e-05	0.00062	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	3.35e-05	0.00062	CcSEcCtD
Dihydroergotamine—Fatigue—Irbesartan—type 2 diabetes mellitus	3.34e-05	0.000617	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	3.32e-05	0.000614	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	3.32e-05	0.000614	CcSEcCtD
Dihydroergotamine—Pain—Irbesartan—type 2 diabetes mellitus	3.31e-05	0.000612	CcSEcCtD
Dihydroergotamine—Insomnia—Losartan—type 2 diabetes mellitus	3.29e-05	0.000609	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	3.28e-05	0.000606	CcSEcCtD
Dihydroergotamine—Paraesthesia—Losartan—type 2 diabetes mellitus	3.27e-05	0.000605	CcSEcCtD
Dihydroergotamine—Urticaria—Metformin—type 2 diabetes mellitus	3.26e-05	0.000602	CcSEcCtD
Dihydroergotamine—Myalgia—Ramipril—type 2 diabetes mellitus	3.26e-05	0.000602	CcSEcCtD
Dihydroergotamine—Arthralgia—Ramipril—type 2 diabetes mellitus	3.26e-05	0.000602	CcSEcCtD
Dihydroergotamine—Dyspnoea—Losartan—type 2 diabetes mellitus	3.25e-05	0.0006	CcSEcCtD
Dihydroergotamine—Anxiety—Ramipril—type 2 diabetes mellitus	3.25e-05	0.0006	CcSEcCtD
Dihydroergotamine—Nausea—Glyburide—type 2 diabetes mellitus	3.24e-05	0.0006	CcSEcCtD
Dihydroergotamine—Abdominal pain—Metformin—type 2 diabetes mellitus	3.24e-05	0.000599	CcSEcCtD
Dihydroergotamine—Dizziness—Gliclazide—type 2 diabetes mellitus	3.24e-05	0.000599	CcSEcCtD
Dihydroergotamine—Somnolence—Losartan—type 2 diabetes mellitus	3.24e-05	0.000599	CcSEcCtD
Dihydroergotamine—Asthenia—Valsartan—type 2 diabetes mellitus	3.23e-05	0.000597	CcSEcCtD
Dihydroergotamine—Discomfort—Ramipril—type 2 diabetes mellitus	3.22e-05	0.000595	CcSEcCtD
Dihydroergotamine—Dyspepsia—Losartan—type 2 diabetes mellitus	3.21e-05	0.000593	CcSEcCtD
Dihydroergotamine—Asthenia—Orlistat—type 2 diabetes mellitus	3.19e-05	0.00059	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	3.19e-05	0.00059	CcSEcCtD
Dihydroergotamine—Pruritus—Valsartan—type 2 diabetes mellitus	3.19e-05	0.000589	CcSEcCtD
Dihydroergotamine—Dry mouth—Ramipril—type 2 diabetes mellitus	3.19e-05	0.000589	CcSEcCtD
Dihydroergotamine—Decreased appetite—Losartan—type 2 diabetes mellitus	3.17e-05	0.000585	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	3.17e-05	0.000585	CcSEcCtD
Dihydroergotamine—Confusional state—Ramipril—type 2 diabetes mellitus	3.15e-05	0.000582	CcSEcCtD
Dihydroergotamine—Pruritus—Orlistat—type 2 diabetes mellitus	3.15e-05	0.000582	CcSEcCtD
Dihydroergotamine—Fatigue—Losartan—type 2 diabetes mellitus	3.14e-05	0.000581	CcSEcCtD
Dihydroergotamine—Oedema—Ramipril—type 2 diabetes mellitus	3.12e-05	0.000577	CcSEcCtD
Dihydroergotamine—Vomiting—Gliclazide—type 2 diabetes mellitus	3.12e-05	0.000576	CcSEcCtD
Dihydroergotamine—Pain—Losartan—type 2 diabetes mellitus	3.12e-05	0.000576	CcSEcCtD
Dihydroergotamine—Rash—Gliclazide—type 2 diabetes mellitus	3.09e-05	0.000571	CcSEcCtD
Dihydroergotamine—Dermatitis—Gliclazide—type 2 diabetes mellitus	3.09e-05	0.000571	CcSEcCtD
Dihydroergotamine—Diarrhoea—Valsartan—type 2 diabetes mellitus	3.08e-05	0.00057	CcSEcCtD
Dihydroergotamine—Urticaria—Irbesartan—type 2 diabetes mellitus	3.08e-05	0.000568	CcSEcCtD
Dihydroergotamine—Shock—Ramipril—type 2 diabetes mellitus	3.07e-05	0.000568	CcSEcCtD
Dihydroergotamine—Headache—Gliclazide—type 2 diabetes mellitus	3.07e-05	0.000568	CcSEcCtD
Dihydroergotamine—Abdominal pain—Irbesartan—type 2 diabetes mellitus	3.06e-05	0.000566	CcSEcCtD
Dihydroergotamine—Body temperature increased—Irbesartan—type 2 diabetes mellitus	3.06e-05	0.000566	CcSEcCtD
Dihydroergotamine—Tachycardia—Ramipril—type 2 diabetes mellitus	3.05e-05	0.000564	CcSEcCtD
Dihydroergotamine—Diarrhoea—Orlistat—type 2 diabetes mellitus	3.05e-05	0.000563	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	3.02e-05	0.000558	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Losartan—type 2 diabetes mellitus	3e-05	0.000555	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	2.98e-05	0.000551	CcSEcCtD
Dihydroergotamine—Dizziness—Valsartan—type 2 diabetes mellitus	2.98e-05	0.000551	CcSEcCtD
Dihydroergotamine—Anorexia—Ramipril—type 2 diabetes mellitus	2.98e-05	0.00055	CcSEcCtD
Dihydroergotamine—HTR1B—cardiovascular system—type 2 diabetes mellitus	2.96e-05	0.0501	CbGeAlD
Dihydroergotamine—Dizziness—Orlistat—type 2 diabetes mellitus	2.94e-05	0.000544	CcSEcCtD
Dihydroergotamine—Asthenia—Metformin—type 2 diabetes mellitus	2.94e-05	0.000544	CcSEcCtD
Dihydroergotamine—Hypotension—Ramipril—type 2 diabetes mellitus	2.92e-05	0.00054	CcSEcCtD
Dihydroergotamine—Nausea—Gliclazide—type 2 diabetes mellitus	2.91e-05	0.000538	CcSEcCtD
Dihydroergotamine—Pruritus—Metformin—type 2 diabetes mellitus	2.9e-05	0.000536	CcSEcCtD
Dihydroergotamine—Urticaria—Losartan—type 2 diabetes mellitus	2.89e-05	0.000535	CcSEcCtD
Dihydroergotamine—Abdominal pain—Losartan—type 2 diabetes mellitus	2.88e-05	0.000532	CcSEcCtD
Dihydroergotamine—Body temperature increased—Losartan—type 2 diabetes mellitus	2.88e-05	0.000532	CcSEcCtD
Dihydroergotamine—HTR1D—cardiovascular system—type 2 diabetes mellitus	2.87e-05	0.0485	CbGeAlD
Dihydroergotamine—Vomiting—Valsartan—type 2 diabetes mellitus	2.86e-05	0.000529	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	2.85e-05	0.000527	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	2.85e-05	0.000526	CcSEcCtD
Dihydroergotamine—Rash—Valsartan—type 2 diabetes mellitus	2.84e-05	0.000525	CcSEcCtD
Dihydroergotamine—Dermatitis—Valsartan—type 2 diabetes mellitus	2.84e-05	0.000525	CcSEcCtD
Dihydroergotamine—Vomiting—Orlistat—type 2 diabetes mellitus	2.83e-05	0.000523	CcSEcCtD
Dihydroergotamine—Insomnia—Ramipril—type 2 diabetes mellitus	2.83e-05	0.000522	CcSEcCtD
Dihydroergotamine—Headache—Valsartan—type 2 diabetes mellitus	2.82e-05	0.000522	CcSEcCtD
Dihydroergotamine—Diarrhoea—Metformin—type 2 diabetes mellitus	2.81e-05	0.000519	CcSEcCtD
Dihydroergotamine—Rash—Orlistat—type 2 diabetes mellitus	2.81e-05	0.000519	CcSEcCtD
Dihydroergotamine—HTR1D—kidney—type 2 diabetes mellitus	2.81e-05	0.0475	CbGeAlD
Dihydroergotamine—Paraesthesia—Ramipril—type 2 diabetes mellitus	2.8e-05	0.000519	CcSEcCtD
Dihydroergotamine—Dermatitis—Orlistat—type 2 diabetes mellitus	2.8e-05	0.000518	CcSEcCtD
Dihydroergotamine—Headache—Orlistat—type 2 diabetes mellitus	2.79e-05	0.000515	CcSEcCtD
Dihydroergotamine—Dyspnoea—Ramipril—type 2 diabetes mellitus	2.78e-05	0.000515	CcSEcCtD
Dihydroergotamine—Asthenia—Irbesartan—type 2 diabetes mellitus	2.78e-05	0.000513	CcSEcCtD
Dihydroergotamine—Somnolence—Ramipril—type 2 diabetes mellitus	2.78e-05	0.000513	CcSEcCtD
Dihydroergotamine—Dyspepsia—Ramipril—type 2 diabetes mellitus	2.75e-05	0.000508	CcSEcCtD
Dihydroergotamine—Pruritus—Irbesartan—type 2 diabetes mellitus	2.74e-05	0.000506	CcSEcCtD
Dihydroergotamine—Decreased appetite—Ramipril—type 2 diabetes mellitus	2.72e-05	0.000502	CcSEcCtD
Dihydroergotamine—Dizziness—Metformin—type 2 diabetes mellitus	2.71e-05	0.000501	CcSEcCtD
Dihydroergotamine—Fatigue—Ramipril—type 2 diabetes mellitus	2.69e-05	0.000498	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Losartan—type 2 diabetes mellitus	2.68e-05	0.000496	CcSEcCtD
Dihydroergotamine—Nausea—Valsartan—type 2 diabetes mellitus	2.68e-05	0.000495	CcSEcCtD
Dihydroergotamine—HTR2B—cardiovascular system—type 2 diabetes mellitus	2.67e-05	0.0451	CbGeAlD
Dihydroergotamine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	2.65e-05	0.00049	CcSEcCtD
Dihydroergotamine—Nausea—Orlistat—type 2 diabetes mellitus	2.64e-05	0.000489	CcSEcCtD
Dihydroergotamine—Asthenia—Losartan—type 2 diabetes mellitus	2.61e-05	0.000483	CcSEcCtD
Dihydroergotamine—Vomiting—Metformin—type 2 diabetes mellitus	2.61e-05	0.000482	CcSEcCtD
Dihydroergotamine—Rash—Metformin—type 2 diabetes mellitus	2.59e-05	0.000478	CcSEcCtD
Dihydroergotamine—Dermatitis—Metformin—type 2 diabetes mellitus	2.58e-05	0.000478	CcSEcCtD
Dihydroergotamine—Pruritus—Losartan—type 2 diabetes mellitus	2.58e-05	0.000476	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Ramipril—type 2 diabetes mellitus	2.57e-05	0.000476	CcSEcCtD
Dihydroergotamine—Headache—Metformin—type 2 diabetes mellitus	2.57e-05	0.000475	CcSEcCtD
Dihydroergotamine—Dizziness—Irbesartan—type 2 diabetes mellitus	2.56e-05	0.000473	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	2.55e-05	0.000472	CcSEcCtD
Dihydroergotamine—HTR2B—cortex of kidney—type 2 diabetes mellitus	2.54e-05	0.043	CbGeAlD
Dihydroergotamine—Diarrhoea—Losartan—type 2 diabetes mellitus	2.49e-05	0.000461	CcSEcCtD
Dihydroergotamine—Urticaria—Ramipril—type 2 diabetes mellitus	2.48e-05	0.000459	CcSEcCtD
Dihydroergotamine—Abdominal pain—Ramipril—type 2 diabetes mellitus	2.47e-05	0.000456	CcSEcCtD
Dihydroergotamine—Body temperature increased—Ramipril—type 2 diabetes mellitus	2.47e-05	0.000456	CcSEcCtD
Dihydroergotamine—Vomiting—Irbesartan—type 2 diabetes mellitus	2.46e-05	0.000455	CcSEcCtD
Dihydroergotamine—Rash—Irbesartan—type 2 diabetes mellitus	2.44e-05	0.000451	CcSEcCtD
Dihydroergotamine—Dermatitis—Irbesartan—type 2 diabetes mellitus	2.44e-05	0.000451	CcSEcCtD
Dihydroergotamine—Nausea—Metformin—type 2 diabetes mellitus	2.44e-05	0.00045	CcSEcCtD
Dihydroergotamine—Headache—Irbesartan—type 2 diabetes mellitus	2.42e-05	0.000448	CcSEcCtD
Dihydroergotamine—Dizziness—Losartan—type 2 diabetes mellitus	2.41e-05	0.000445	CcSEcCtD
Dihydroergotamine—HTR1A—cardiovascular system—type 2 diabetes mellitus	2.39e-05	0.0404	CbGeAlD
Dihydroergotamine—HTR2B—adipose tissue—type 2 diabetes mellitus	2.35e-05	0.0398	CbGeAlD
Dihydroergotamine—Vomiting—Losartan—type 2 diabetes mellitus	2.32e-05	0.000428	CcSEcCtD
Dihydroergotamine—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	2.32e-05	0.0392	CbGeAlD
Dihydroergotamine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	2.3e-05	0.000425	CcSEcCtD
Dihydroergotamine—Nausea—Irbesartan—type 2 diabetes mellitus	2.3e-05	0.000425	CcSEcCtD
Dihydroergotamine—Rash—Losartan—type 2 diabetes mellitus	2.3e-05	0.000425	CcSEcCtD
Dihydroergotamine—Dermatitis—Losartan—type 2 diabetes mellitus	2.29e-05	0.000424	CcSEcCtD
Dihydroergotamine—Headache—Losartan—type 2 diabetes mellitus	2.28e-05	0.000422	CcSEcCtD
Dihydroergotamine—Asthenia—Ramipril—type 2 diabetes mellitus	2.24e-05	0.000414	CcSEcCtD
Dihydroergotamine—Pruritus—Ramipril—type 2 diabetes mellitus	2.21e-05	0.000409	CcSEcCtD
Dihydroergotamine—Nausea—Losartan—type 2 diabetes mellitus	2.16e-05	0.0004	CcSEcCtD
Dihydroergotamine—Diarrhoea—Ramipril—type 2 diabetes mellitus	2.14e-05	0.000395	CcSEcCtD
Dihydroergotamine—Dizziness—Ramipril—type 2 diabetes mellitus	2.07e-05	0.000382	CcSEcCtD
Dihydroergotamine—Vomiting—Ramipril—type 2 diabetes mellitus	1.99e-05	0.000367	CcSEcCtD
Dihydroergotamine—Rash—Ramipril—type 2 diabetes mellitus	1.97e-05	0.000364	CcSEcCtD
Dihydroergotamine—Dermatitis—Ramipril—type 2 diabetes mellitus	1.97e-05	0.000364	CcSEcCtD
Dihydroergotamine—Headache—Ramipril—type 2 diabetes mellitus	1.96e-05	0.000362	CcSEcCtD
Dihydroergotamine—Nausea—Ramipril—type 2 diabetes mellitus	1.86e-05	0.000343	CcSEcCtD
Dihydroergotamine—ADRA2A—pancreas—type 2 diabetes mellitus	1.63e-05	0.0275	CbGeAlD
Dihydroergotamine—ADRA2A—cortex of kidney—type 2 diabetes mellitus	1.6e-05	0.027	CbGeAlD
Dihydroergotamine—ADRA2A—adipose tissue—type 2 diabetes mellitus	1.48e-05	0.025	CbGeAlD
Dihydroergotamine—ABCB1—islet of Langerhans—type 2 diabetes mellitus	1.29e-05	0.0218	CbGeAlD
Dihydroergotamine—CYP3A4—kidney—type 2 diabetes mellitus	1.29e-05	0.0218	CbGeAlD
Dihydroergotamine—ABCB1—retina—type 2 diabetes mellitus	1.1e-05	0.0187	CbGeAlD
Dihydroergotamine—ABCB1—nephron tubule—type 2 diabetes mellitus	1.04e-05	0.0176	CbGeAlD
Dihydroergotamine—ABCB1—cardiovascular system—type 2 diabetes mellitus	9.33e-06	0.0158	CbGeAlD
Dihydroergotamine—ABCB1—kidney—type 2 diabetes mellitus	9.13e-06	0.0155	CbGeAlD
Dihydroergotamine—ABCB1—pancreas—type 2 diabetes mellitus	9.07e-06	0.0153	CbGeAlD
Dihydroergotamine—ABCB1—cortex of kidney—type 2 diabetes mellitus	8.89e-06	0.015	CbGeAlD
Dihydroergotamine—ABCB1—adipose tissue—type 2 diabetes mellitus	8.23e-06	0.0139	CbGeAlD
Dihydroergotamine—CYP3A4—liver—type 2 diabetes mellitus	8.15e-06	0.0138	CbGeAlD
Dihydroergotamine—ABCB1—liver—type 2 diabetes mellitus	5.77e-06	0.00977	CbGeAlD
Dihydroergotamine—ADRA2A—Metabolism—GPX1—type 2 diabetes mellitus	2.02e-06	8.21e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	2.01e-06	8.18e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	2.01e-06	8.16e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	2e-06	8.15e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IGF1—type 2 diabetes mellitus	2e-06	8.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT2—type 2 diabetes mellitus	2e-06	8.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.99e-06	8.1e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—C3—type 2 diabetes mellitus	1.98e-06	8.06e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CD36—type 2 diabetes mellitus	1.97e-06	8e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.96e-06	7.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—INS—type 2 diabetes mellitus	1.95e-06	7.91e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPP2CA—type 2 diabetes mellitus	1.94e-06	7.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.94e-06	7.9e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	1.93e-06	7.83e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.92e-06	7.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.91e-06	7.78e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	1.9e-06	7.74e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	1.9e-06	7.74e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.9e-06	7.73e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.9e-06	7.73e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.89e-06	7.69e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.89e-06	7.67e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AGT—type 2 diabetes mellitus	1.89e-06	7.66e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	1.89e-06	7.66e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.88e-06	7.65e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.88e-06	7.64e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.88e-06	7.63e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	1.88e-06	7.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.87e-06	7.61e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.87e-06	7.6e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.87e-06	7.6e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.87e-06	7.59e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MTHFR—type 2 diabetes mellitus	1.87e-06	7.58e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.86e-06	7.56e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	1.86e-06	7.55e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.86e-06	7.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.86e-06	7.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.85e-06	7.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—LEP—type 2 diabetes mellitus	1.85e-06	7.51e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOE—type 2 diabetes mellitus	1.85e-06	7.51e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.84e-06	7.48e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARA—type 2 diabetes mellitus	1.83e-06	7.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.83e-06	7.42e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	1.83e-06	7.42e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	1.83e-06	7.42e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	1.82e-06	7.4e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	1.82e-06	7.4e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	1.82e-06	7.4e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	1.82e-06	7.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.82e-06	7.38e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.82e-06	7.38e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	1.81e-06	7.37e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.81e-06	7.34e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.79e-06	7.26e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.79e-06	7.26e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AGT—type 2 diabetes mellitus	1.77e-06	7.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—RELA—type 2 diabetes mellitus	1.76e-06	7.15e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—RELA—type 2 diabetes mellitus	1.75e-06	7.1e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	1.75e-06	7.09e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CALM1—type 2 diabetes mellitus	1.74e-06	7.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.74e-06	7.08e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOE—type 2 diabetes mellitus	1.74e-06	7.06e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	1.73e-06	7.04e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOA1—type 2 diabetes mellitus	1.72e-06	6.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—RELA—type 2 diabetes mellitus	1.71e-06	6.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.71e-06	6.94e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.71e-06	6.94e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.7e-06	6.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.65e-06	6.7e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.63e-06	6.6e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	1.62e-06	6.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—RELA—type 2 diabetes mellitus	1.61e-06	6.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.6e-06	6.51e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.6e-06	6.49e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.59e-06	6.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.59e-06	6.45e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—INS—type 2 diabetes mellitus	1.58e-06	6.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.58e-06	6.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.58e-06	6.4e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.57e-06	6.39e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	1.57e-06	6.39e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	1.57e-06	6.36e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.57e-06	6.36e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	1.56e-06	6.34e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.56e-06	6.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.55e-06	6.31e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	1.55e-06	6.28e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.54e-06	6.27e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.53e-06	6.23e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.53e-06	6.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.53e-06	6.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.52e-06	6.17e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	1.51e-06	6.16e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	1.51e-06	6.15e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	1.5e-06	6.1e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.5e-06	6.1e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.49e-06	6.05e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.49e-06	6.04e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.48e-06	6.03e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	1.48e-06	6.03e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	1.48e-06	6.03e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.48e-06	6.03e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	1.48e-06	6.03e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	1.48e-06	6.02e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	1.47e-06	5.99e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.47e-06	5.99e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.46e-06	5.94e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	1.46e-06	5.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.46e-06	5.92e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.46e-06	5.92e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	1.46e-06	5.91e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.45e-06	5.91e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	1.45e-06	5.9e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	1.45e-06	5.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.45e-06	5.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.45e-06	5.89e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	1.45e-06	5.88e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	1.45e-06	5.88e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	1.45e-06	5.88e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.44e-06	5.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.44e-06	5.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.44e-06	5.85e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	1.44e-06	5.84e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.44e-06	5.83e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	1.43e-06	5.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.41e-06	5.75e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	1.41e-06	5.74e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	1.4e-06	5.7e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	1.4e-06	5.68e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	1.4e-06	5.67e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.38e-06	5.62e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.38e-06	5.62e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SRC—type 2 diabetes mellitus	1.38e-06	5.62e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SRC—type 2 diabetes mellitus	1.37e-06	5.58e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.37e-06	5.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.37e-06	5.56e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	1.36e-06	5.53e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	1.36e-06	5.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.35e-06	5.51e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.35e-06	5.47e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.34e-06	5.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.34e-06	5.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.34e-06	5.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.33e-06	5.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.31e-06	5.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.3e-06	5.29e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	1.3e-06	5.29e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	1.3e-06	5.29e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.3e-06	5.27e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.3e-06	5.27e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.3e-06	5.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.3e-06	5.26e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	1.29e-06	5.24e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.27e-06	5.17e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	1.27e-06	5.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.26e-06	5.13e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.26e-06	5.13e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	1.24e-06	5.04e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.24e-06	5.02e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.23e-06	5.02e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.23e-06	5e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.23e-06	4.99e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	1.23e-06	4.98e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.22e-06	4.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.21e-06	4.93e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	1.21e-06	4.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.2e-06	4.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.2e-06	4.88e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	1.2e-06	4.88e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.2e-06	4.88e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.2e-06	4.87e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.19e-06	4.85e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	1.19e-06	4.84e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	1.19e-06	4.82e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.19e-06	4.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.19e-06	4.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.18e-06	4.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.18e-06	4.78e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.17e-06	4.77e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.17e-06	4.77e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.17e-06	4.74e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.14e-06	4.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.13e-06	4.59e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.12e-06	4.57e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.12e-06	4.57e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.11e-06	4.51e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.11e-06	4.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.1e-06	4.46e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.09e-06	4.42e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.09e-06	4.42e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.08e-06	4.38e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.05e-06	4.25e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.03e-06	4.17e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.02e-06	4.16e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.02e-06	4.16e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.97e-07	4.05e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	9.69e-07	3.94e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	9.69e-07	3.94e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	9.65e-07	3.92e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	9.52e-07	3.87e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	9.4e-07	3.82e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.32e-07	3.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—type 2 diabetes mellitus	9.32e-07	3.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—type 2 diabetes mellitus	9.25e-07	3.76e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	9.24e-07	3.76e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.24e-07	3.75e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.18e-07	3.73e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.15e-07	3.72e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—type 2 diabetes mellitus	9.05e-07	3.68e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	9e-07	3.66e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	9e-07	3.66e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	8.99e-07	3.65e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.97e-07	3.65e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	8.83e-07	3.59e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.73e-07	3.55e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	8.64e-07	3.51e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.63e-07	3.51e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	8.61e-07	3.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.59e-07	3.49e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.53e-07	3.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—type 2 diabetes mellitus	8.5e-07	3.46e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.46e-07	3.44e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	8.39e-07	3.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.35e-07	3.39e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	8.28e-07	3.37e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	8.23e-07	3.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	8.05e-07	3.27e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	7.95e-07	3.23e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.85e-07	3.19e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.84e-07	3.18e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	7.8e-07	3.17e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	7.55e-07	3.07e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	7.42e-07	3.02e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	7.4e-07	3.01e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	7.31e-07	2.97e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.19e-07	2.92e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.05e-07	2.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—type 2 diabetes mellitus	6.9e-07	2.8e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	6.44e-07	2.62e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.36e-07	2.59e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	6.32e-07	2.57e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	5.98e-07	2.43e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	5.79e-07	2.35e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	5.54e-07	2.25e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	5.54e-07	2.25e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	5.42e-07	2.2e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	5.07e-07	2.06e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	5e-07	2.03e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	4.14e-07	1.68e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	2.55e-07	1.04e-05	CbGpPWpGaD
